Outcomes of COVID-19 in Ofatumumab-treated Patients with RMS: Data from the ALITHIOS Open-label Extension Study

Author:Boer, Ibolya   Cree, Bruce   Wiendl, Heinz   Cross, Anne   Delgado, Sylvia   Habek, Mario   Khachanova, Natalia   Ward, Brian   Totolyan, Natalia   Mancione, Linda   Sullivan, Roseanne   Zielman, Ronald   Hu, Xixi   Das Gupta, Ayan   Montalban, Xavier   Winthrop, Kevin   

Session Name:P1: Multiple Sclerosis: Clinical Practice and Decision Making 1  

Topic:Multiple Sclerosis  

Program Number:P1.010  

Author Institution:Novartis Pharma AG, Basel, Switzerland  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA  Department of Neurology with Institute of Translational Neurology, University of Münster, Muenster, Germany  Washington University School of Medicine, Saint Louis, MO  University of Miami Miller School of Medicine, Miami, FL  University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia  Pirogov Russian National Research Medical University, Moscow, Russian Federation  Infectious Diseases Division, Research Institute of the McGill University Health Centre, Montreal, QC, Canada  First Saint Petersburg State Medical University, St Petersburg , Russian Federation  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Novartis Pharma B.V, Amsterdam, Netherlands  Novartis Healthcare Private Limited, Hyderabad, India  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain  School of Public Health at Oregon Health & Science University, Portland, OR